Literature DB >> 10452998

Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells.

D C Tsitoura1, R H DeKruyff, J R Lamb, D T Umetsu.   

Abstract

In this study we examined the immunological parameters underlying the natural immunity to inhaled nonpathogenic proteins. We addressed this question by examining the effect of intranasal exposure to OVA in both wild-type mice and mice reconstituted with OVA-TCR transgenic CD4+ T cells. Intranasal administration of OVA induced an initial phase of activation during which CD4+ T cells were capable of proliferating and producing cytokines. Although many of the OVA-specific CD4+ T cells were subsequently depleted from the lymphoid organs, a stable population of such T cells survived but remained refractory to antigenic rechallenge. The unresponsive state was not associated with immune deviation due to selective secretion of Th1- or Th2-type cytokines, and the presence of regulatory CD8+ T cells was not required. Moreover, neutralization of the immunosuppressive cytokines IL-10 and TGF-beta did not abrogate the induction of tolerance. Inhibition of the interaction of T cells with CD86, but not CD80, at the time of exposure to intranasal Ag prevented the development of unresponsiveness, while selective blockade of CTLA-4 had no effect. Our results suggest that intranasal exposure to Ags results in immunological tolerance mediated by functionally impaired CD4+ T cells via a costimulatory pathway that requires CD86.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452998

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy.

Authors:  A D Dick; V Sharma; J Liversidge
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

3.  Inducible CD4+LAP+Foxp3- regulatory T cells suppress allergic inflammation.

Authors:  Wei Duan; Takanori So; Amit K Mehta; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

4.  Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen.

Authors:  Richard Verbeek; Koen van der Mark; Eric F Wawrousek; Arianne C Plomp; Johannes M van Noort
Journal:  Immunology       Date:  2007-04-26       Impact factor: 7.397

5.  Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cells.

Authors:  Bharati Matta; Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

6.  Activation of nonclassical CD1d-restricted NK T cells induces airway hyperreactivity in beta 2-microglobulin-deficient mice.

Authors:  Youngil I Koh; Hye Young Kim; Everett H Meyer; Muriel Pichavant; Omid Akbari; Takahiro Yasumi; Paul B Savage; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

7.  A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity.

Authors:  Vincent Lombardi; Philippe Stock; Abinav K Singh; Jerome Kerzerho; Wen Yang; Barbara A Sullivan; Xiangming Li; Takayuki Shiratsuchi; Nathan E Hnatiuk; Amy R Howell; Karl O A Yu; Steven A Porcelli; Moriya Tsuji; Mitchell Kronenberg; S Brian Wilson; Omid Akbari
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

8.  Inhibition of Th2 adaptive immune responses and pulmonary inflammation by leukocyte Ig-like receptor B4 on dendritic cells.

Authors:  Rebecca G Breslow; Jayanti J Rao; Wei Xing; David I Hong; Nora A Barrett; Howard R Katz
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

9.  Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease.

Authors:  R D Garman; K Munroe; S M Richards
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

10.  Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.

Authors:  K Hufnagl; B Wagner; B Winkler; K Baier; R Hochreiter; J Thalhamer; D Kraft; O Scheiner; H Breiteneder; U Wiedermann
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.